# OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

> **NCT04791007** · EARLY_PHASE1 · COMPLETED · sponsor: **Orion Biotechnology Polska Sp. z o.o.** · enrollment: 60 (actual)

## Conditions studied

- HIV Prevention

## Interventions

- **DRUG:** OB-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04791007
- **Lead sponsor:** Orion Biotechnology Polska Sp. z o.o.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-05
- **Primary completion:** 2020-04-06
- **Final completion:** 2020-08-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04791007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04791007, "OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04791007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*